Skip to content
POM-V Prescription Required Companion Animal

Merilym 3, Suspension for Injection for Dogs

Active ingredients: Borrelia afzelii, Borrelia burgdorferi sensu stricto, Borrelia garinii

Form

Injection

Species

Dogs

Manufacturer

Boehringer Ingelheim Animal Health UK Limited

VMD MA No.

08327/5035

What it's used for

For active immunization of dogs from 12 weeks of age, to induce an anti-OspA response against Borrelia spp. (B. burgdorferi, B. garinii and B. afzelii). Re...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Borrelia afzelii + Borrelia...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Merilym 3, Suspension for Injection for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For active immunization of dogs from 12 weeks of age, to induce an anti-OspA
response against Borrelia spp. (B. burgdorferi, B. garinii and B. afzelii).
Reduction of Borrelia transmission was only investigated under laboratory conditions,
following a challenge with field ticks (collected from a region known to be affected by
Borrelia). Under these conditions, it was shown that no Borrelia could be isolated
from the skin of vaccinated dogs, while Borrelia were isolated from the skin of non
vaccinated dogs.
Reduction of transmission of Borrelia from the tick to the host has not been
quantified, and no correlation has been established between a specific level of

Amended pages: January 2025
AN: 02809/2023
antibodies and reduction of Borrelia transmission. The efficacy of the vaccine against
an infection that leads to the development of clinical disease has not been studied.
Onset of immunity: 1 month after primary vaccination.
Duration of immunity: 1 year after primary vaccination.
Do not use in case of general febrile illness.
Do not use in sick animals that have intercurrent disease, heavy parasitic infestation
and/or are in poor general condition.
Do not use in case of suspected or confirmed clinical Lyme borreliosis.
Do not use in cases of hypersensitivity to the active substances, to the adjuvant or to
any of the excipients.
Dogs:
Rare
(1 to 10 animals / 10 000 animals
treated):
Injection site swelling.
Anorexia, lethargy.
Very rare
(<1 animal / 10 000 animals
treated, including isolated
reports):
Injection site swelling.
Elevated temperature.
Hypersensitivity reaction.
1
Up to 7 cm in diameter, for up to 5 days.
Up to 15 cm in diameter.
Transient, up to 1.5°C.
Which may require appropriate symptomatic treatment.

Amended pages: January 2025
AN: 02809/2023
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Vaccinate healthy animals only.

Special precautions for use in animals
No information is available on the use of the vaccine in seropositive animals including
those with maternally derived antibodies.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Not applicable.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.
Protect from light.
Store and transport refrigerated (2 °C – 8 °C).
Not applicable.

Amended pages: January 2025
AN: 02809/2023
5. IMMUNOLOGICAL PROPERTIES
ATCvet code: QI07AB04
The vaccine induces specific anti-OspA antibodies against Borrelia burgdorferi sensu
lato. Scientific literature are available which indicate that during a tick blood feeding,
vaccine-induced antibodies present in the blood are ingested by the tick and are
expected to bind to OspA proteins expressed by the bacteria in the tick gut; this is
expected to reduce their migration to the salivary glands and transmission to the
host.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance
Same active ingredient

Other Products Containing Borrelia afzelii

These products share the same active ingredient and may be suitable alternatives. Always consult your vet.

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.